ArticleBMC pharmacology & toxicology2026
Preparation, molecular docking, and biological evaluation of radioiodinated cefaclor for inflammation detection.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammation serves as a natural defense mechanism; however, its persistence can lead to chronic diseases with serious clinical consequences. Early detection of inflammation is therefore critical to slowing disease progression and improving therapeutic outcomes.
methodsIn this study, cefaclor (Cefa) was successfully radiolabeled with iodine-131 via electrophilic substitution to facilitate the detection of infected and inflamed muscles in mouse models. The labeling reaction was carried out with 100 µg of Cefa and 100 µg of iodogen, using glass frits as the oxidizing system at pH 7 and 60 °C, with 10 µL of Na131I for 20 min. The resulting [131I]Cefa was purified by high-performance liquid chromatography (HPLC). Molecular modeling was performed in the Molecular Operating Environment (MOE) to evaluate the compound’s structure and binding affinity.
resultsThe labeling process was optimized to achieve a radiolabeling efficiency of 90 ± 0.56%, and stability of about 89 ± 0.5% at 4 h. Docking simulations confirmed strong binding of [131I]Cefa to bacterial DNA gyrase B, supporting its potential as a targeted imaging agent. Biological evaluation in mouse models demonstrated notable tracer accumulation in both septic and sterile inflammatory sites. Uptake values reached 28 ± 1.5%ID/organ in infected muscles and 16 ± 1.5%ID/organ in sterile inflammation at 120 minutes post-injection. The target-to-non-target (T/NT) ratios were 5.28 for infected muscles and 2.1 for sterile inflammation, indicating effective differentiation between bacterial (septic) and non-bacterial (aseptic) inflammatory foci.
conclusionThe radiolabeled [131I]Cefa compound exhibits promising diagnostic capabilities for distinguishing bacterial infections from sterile inflammation. Its high radiolabeling efficiency, strong molecular binding, and selective in vivo uptake support its potential utility as a non-invasive imaging agent for early detection and characterization of inflammatory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.